Moderna and Merck are developing a treatment using an mRNA-based cancer vaccine called intismeran that is designed to be tailored to individual patients based on unique mutations within their tumors.
Moderna and Merck are developing a treatment using an mRNA-based cancer vaccine called intismeran that is designed to be tailored to individual patients based on unique mutations within their tumors.
<iframe src="https://statesidedaily.com/embed/cluster/92228c7083403acf8a5c14dedf75a31db22280d5" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Moderna shares surge after it says experimental mRNA cancer treatment passed key test"></iframe>
